SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3496-3499. Prepublished online as a Blood First Edition Paper on December 27, 2006; DOI 10.1182/blood-2006-07-036012. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2006-07-036012v1 109/8/3496    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Picard, S. Articles by Mahon, F.-X. Search for Related Content PubMed PubMed Citation Articles by Picard, S. Articles by Mahon, F.-X. Related Collections Oncogenes and Tumor Suppressors Brief Reports Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief Report Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Stephane Picard1,2,3, Karine Titier1,2,3, Gabriel Etienne4, Emmanuelle Teilhet1,2,3, Dominique Ducint1,2,3, Marie-Agnes Bernard1, Regis Lassalle1, Gerald Marit2,5,6, Josy Reiffers4, Bernard Begaud1,2,3, Nicholas Moore1,2,3, Mathieu Molimard1,2,3, and Francois-Xavier Mahon2,5,6 1 Department of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France; 2 University Victor Ségalen Bordeaux 2, Bordeaux, France; 3 Institut National de la Santé et de la Recherche Médicale (INSERM) U657, Bordeaux, France; 4 Department of Hematology, the Institut Bergonié, Regional Cancer Center, Bordeaux, France; 5 Department of Hematology and Blood Diseases, CHU de Bordeaux, Bordeaux, France; 6 INSERM E217, Bordeaux, France    Abstract Top Abstract Introduction Patients and methods Results and discussion Authorship References   Using high-performance liquid chromatography–tandem mass spectrometry, we assessed trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who responded or not to standard-dose imatinib, after at least 12 months' treatment. Mean trough imatinib plasma levels were significantly higher in the group with complete cytogenetic response (56 patients) than in the group without (12 patients; P = .03) and higher in the group with major molecular response (MMR) than in the group without (34 patients [1452 ± 649 ng/mL] versus 34 patients [869 ± 427 ng/mL]; P < .001). Regarding trough imatinib plasma levels and their discrimination potential for MMR, the area under receiver operating characteristic curve was 0.775, with best sensitivity (77%) and specificity (71%) at a plasma threshold of 1002 ng/mL. Therefore, monitoring of imatinib plasma levels could be very useful for the management of patients with CML or should at least be checked in the case of treatment failure or suboptimal response.    Introduction Top Abstract Introduction Patients and methods Results and discussion Authorship References   Continuing progress in the treatment of chronic myeloid leukemia (CML) lies in a better understanding of the disease pathobiology and the mechanisms of treatment failures. Imatinib (Gleevec or Glivec) is a competitive inhibitor of the Bcr-Abl tyrosine kinase, a constitutively active oncoprotein involved in CML pathogenesis. Bcr-Abl is the product of the BCR-ABL fusion gene that results from the reciprocal translocation between chromosomes 9 and 22, which is cytogenetically visible as the Philadelphia chromosome.1,2 Despite the excellent efficacy of imatinib, cases of treatment failure or suboptimal response have been reported. Previous studies identified cellular mechanisms of resistance to imatinib such as gene mutations in the kinase domain of Bcr-Abl, BCR-ABL gene amplification, overexpression of Src-related kinases, drug efflux mediated by the P-glycoprotein which is encoded by the MDR1 gene.3–7 Another hypothesis to explain variable responses to imatinib therapy lies in pharmacokinetic variability.8–10 Too low trough imatinib plasma levels could indicate an ineffective drug regimen, insufficient to achieve complete cytogenetic response (CCR) or major molecular response (MMR). To test this hypothesis, we measured trough imatinib plasma levels in patients with CML and compared them with the likelihood of achieving CCR or MMR to standard-dose imatinib.    Patients and methods Top Abstract Introduction Patients and methods Results and discussion Authorship References   All patients provided informed consent to participate in this study, which was performed parallel to the molecular evaluation. The study was approved by the local Ethics Committee. Pharmacologists who performed the analysis for this study had no direct contact with humans. Patients with chronic-phase or accelerated-phase CML were considered for our study. Patients were treated orally, for at least 12 months, with standard-dose imatinib (ie, 400 mg or 600 mg once daily for chronic-phase or accelerated-phase CML, respectively), according to the phase 2 expanded access protocols (109, 110, 113, 114) and a phase 3 trial (106) supported by Novartis Pharma and the French SPIRIT study. Exclusion criteria were initiation of imatinib therapy less than 12 months before, blast crisis before or during imatinib therapy, blood collection performed out of the trough concentration time limits, poor compliance to treatment, identification of gene mutation(s) in the kinase domain of Bcr-Abl. Cytogenetic responses to imatinib were assessed using a conventional cytogenetic analysis of bone marrow metaphases. CCR was defined as 0% of Philadelphia chromosome–positive cells in the bone marrow aspirate.11 To assess molecular responses, total RNA was extracted from peripheral blood cells, and BCR-ABL transcript levels were quantified using real-time quantitative reverse-transcriptase polymerase chain reaction,11 according to recommendations recently proposed for harmonization of results.12 MMR was defined as a reduction in BCR-ABL transcript levels of at least 3 log after 12 months of imatinib therapy, from a standardized baseline.13 For imatinib plasma quantification, blood samples were collected between 21 and 27 hours after last drug administration. Trough imatinib plasma levels were determined using high-performance liquid chromatography coupled to electrospray-ionization tandem mass spectrometry.14 Student t test or Wilcoxon rank test was used to compare means between 2 groups. Comparisons of proportions were performed using a chi-square test or exact Fisher test. Receiver operating characteristic (ROC) curve analysis was performed to assess a discrimination potential of trough imatinib plasma levels for MMR.    Results and discussion Top Abstract Introduction Patients and methods Results and discussion Authorship References   Ninety-five patients with CML were considered for participation in the study. One patient was excluded because he was found to be in blast crisis. Twenty-four patients were excluded because of inadequate blood collection (ie, performed out of time limits). One patient was excluded because of recognized poor compliance to therapy. One patient was excluded because a G250E mutation was identified in the kinase domain of Bcr-Abl. Finally, 68 patients with CML were included for investigation: 50 patients and 18 patients were treated with imatinib 400 mg and 600 mg daily, respectively. Trough imatinib plasma levels were highly variable, ranging from 181 to 2947 ng/mL; means and SDs were 1058 ± 557 ng/mL and 1444 ± 710 ng/mL for the 400-mg and 600-mg daily dose regimen, respectively. These data confirm the high variability previously described between subjects in trough imatinib plasma levels.8 Such intersubject variability may be multifactorial, including diverse determinants such as genetic polymorphisms, environmental factors, concomitant diseases, or coadministered drugs.10 These determinants may be involved in the pharmacokinetic of imatinib: absorption, distribution, metabolism (involvement of cytochrome P-450 enzymes9 CYP3A4 and CYP3A5), or excretion. The role of efflux transporters such as ABCB1 (P-glycoprotein) and ABCG2 or organic cation transporter OCT1 cannot be excluded, but these transporters modify mainly the intracellular concentration of the drug. Main characteristics of the 68 patients with CML, classified as those with (n = 34) or without (n = 34) MMR, are summarized in Table 1. Mean (± SD) trough imatinib plasma levels were significantly higher in the group with MMR than in the group without (P < .001). No significant difference was found in the imatinib daily dose between patients with or without MMR. Mean (± SD) trough imatinib plasma levels were significantly higher in the group with CCR than in the group without (56 patients [1123 ± 617 ng/mL] versus 12 patients [694 ± 556 ng/mL]; P =.03). Moreover, MMR to treatment was not significantly associated with the time elapsed between initiation of imatinib therapy and molecular analysis: mean (± SD) values were 986 ± 427 days and 966 ± 560 days in groups with and without MMR, respectively (P =.87). Our results show that trough imatinib plasma levels are associated with the likelihood of achieving CCR or MMR to standard-dose imatinib. View this table: [in this window] [in a new window]   Table 1. Patients' characteristics according to molecular response to standard-dose imatinib therapy   The concentration-effect ROC curve analysis shows the discrimination potential of trough imatinib plasma levels for MMR (Figure 1A). A plasma threshold of 1002 ng/mL was significantly associated with the presence of MMR (odds ratio = 7.80; 95% confidence interval, 2.64-23.03; P < .001). Box plots of trough imatinib plasma levels (Figure 1B) show the dispersion around the median for patients with or without MMR. Regarding the box plot graph, the initially described target concentration (493.6 ng/mL, ie, 1 µmol/L) required to result in BCR-ABL–positive cell death in vitro8,15,16 is not always sufficient to achieve MMR in vivo. Our results suggest that the efficient plasma threshold for trough imatinib levels should be set above 1002 ng/mL in vivo. View larger version (13K): [in this window] [in a new window]   Figure 1. Trough plasma imatinib threshold for major molecular response (MMR).(A) Receiver operating characteristic (ROC) curve analysis. Regarding trough imatinib plasma levels and their discrimination potential for MMR, the area under the ROC curve (AUC) was 0.775, with best sensitivity (77%) and specificity (71%) at a plasma threshold of 1002 ng imatinib/mL. (B) Box plots of trough imatinib plasma levels. The graph shows the dispersion around the median for patients with MMR (n = 34; median = 1350 ng/mL) and those without (n = 34; median = 885 ng/mL). The line across each box is the median; the bottom edge is the first quartile and the top edge is the third quartile; the error bars represent minimal and maximal values; the bottom line shows the 493.6 ng/mL (ie, 1 µmol/L) target concentration required to result in BCR-ABL–positive cell death in vitro; the top line shows the 1002 ng/mL efficient plasma threshold for trough imatinib levels in vivo. Of the 34 patients with MMR, 26 (76%) had trough imatinib plasma levels exceeding the 1002 ng/mL threshold. Of the 34 patients without MMR, 24 (71%) had trough imatinib plasma levels below the 1002 ng/mL threshold, whereas 27 patients (79%) had trough imatinib plasma levels exceeding the initially described target concentration (493.6 ng/mL) required to result in BCR-ABL–positive cell death in vitro.8,15,16 This initial target was validated in phase 1 to 2 studies on the basis of cytogenetic criteria, but it is not always sufficient to achieve MMR in vivo. Indeed, using a sharper criterion than CCR such as a 3 log reduction of BCR-ABL transcript levels, the efficient plasma threshold for trough imatinib levels should be set above 1002 ng/mL in vivo.   Too low trough imatinib plasma levels could lead to an ineffective drug regimen, imatinib levels being insufficient to achieve CCR or MMR. The reasons for low plasma levels of imatinib need to be identified: poor compliance to daily oral therapy, drug-drug interactions, food interaction, concomitant disease, or genetic polymorphism. Kantarjian et al17 have suggested that patients treated with high-dose imatinib had significantly higher rates of CCR and MMR than those receiving standard dose. The same group demonstrated that dose escalation of imatinib could overcome resistance in some patients with CML initially treated with standard-dose therapy.18 Dose escalation can be associated with an increased rate of side effects. In patients failing to achieve cytogenetic or molecular response, the quantification of trough imatinib plasma levels could become of interest to optimize treatment. Dose escalation may be considered for patients with low plasma levels of imatinib. In patients with trough imatinib plasma levels exceeding 1002 ng/mL, cellular resistance to imatinib and subsequent alternative therapy, such as new kinase-inhibitor nilotinib or dasatinib,19,20 should be considered. Trough imatinib plasma levels are associated with both CCR and MMR to standard-dose imatinib in CML, with a plasma threshold of 1002 ng imatinib/mL in vivo. Our results suggest monitoring imatinib plasma levels to adjust treatment strategies in patients with CML. However, a study in patients with de novo CML with analyses at different time points (1 or 2 per year) would be useful to validate this plasma threshold and confirm our study. Leading to dosage optimization on a patient-by-patient basis, the rational quantification of imatinib blood levels could become a key feature of clinical practice in CML, with the goal of a better understanding of treatment failure or suboptimal response in patients receiving standard-dose imatinib. A prospective study is in progress to validate the impact of dose escalation in taking into account trough imatinib plasma levels on the response.    Authorship Top Abstract Introduction Patients and methods Results and discussion Authorship References   Contribution: S.P., M.M., and F.-X.M. collaborated in the conception and design of the study. S.P., K.T., G.E., E.T., D.D., M.-A.B., and F.-X.M. did the experiments and performed data analysis. All authors contributed to data interpretation. S.P. wrote the article. All authors revised it critically for the intellectual content. All authors collaborated in the final approval of the version to be published. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: François-Xavier Mahon, Laboratoire Hématopoïèse normale et pathologique, Université Victor Ségalen Bordeaux 2, 146 rue Léo Saignat, INSERM E217, 33076 Bordeaux, France; e-mail: francois-xavier.mahon{at}umr5540.u-bordeaux2.fr.    Footnotes   Submitted July 20, 2006; accepted December 6, 2006. Prepublished online as Blood First Edition Paper, December 27, 2006 DOI: 10.1182/blood-2006-07-036012 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Patients and methods Results and discussion Authorship References   Savage DG and Antman KH. Imatinib mesylate—a new oral targeted therapy. N Engl J Med 2002; 346:683–693.[Free Full Text] Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031–1037.[Abstract/Free Full Text] Walz C and Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006; 57:145–164.[Medline] [Order article via Infotrieve] Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876–880.[Abstract/Free Full Text] Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96:1070–1079.[Abstract/Free Full Text] Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101:690–698.[Abstract/Free Full Text] Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101:2368–2373.[Abstract/Free Full Text] Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22:935–942.[Abstract/Free Full Text] Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44:879–894.[CrossRef][Medline] [Order article via Infotrieve] Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352:2211–2221.[Free Full Text] Colombat M, Fort MP, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006; 91:162–168.[Abstract/Free Full Text] Hughes TP, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors : review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28–37.[Abstract/Free Full Text] Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) study group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423–1432.[Abstract/Free Full Text] Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005; 27:634–640 [Erratum, Ther Drug Monit. 2005;27:810].[CrossRef][Medline] [Order article via Infotrieve] Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100–104.[Abstract/Free Full Text] Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561–566.[CrossRef][Medline] [Order article via Infotrieve] Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103:2873–2878.[Abstract/Free Full Text] Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473–475.[Abstract/Free Full Text] Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542–2551.[Abstract/Free Full Text] Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531–2541.[Abstract/Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Therapeutic drug monitoring in CML patients on imatinib Carolyn Blasdel, Merrill J. Egorin, Theodore F. Lagattuta, Brian J. Druker, and Michael W. Deininger Blood 2007 110: 1699-1701. [Full Text] [PDF] Use of therapeutic drug monitoring in CML patients on imatinib François-Xavier Mahon, Stéphane Picard, Gerald Marit, Philip Robinson, and Mathieu Molimard Blood 2007 110: 1701. [Full Text] [PDF] This article has been cited by other articles: J. L. Snead, T. O'Hare, L. T. Adrian, C. A. Eide, T. Lange, B. J. Druker, and M. W. Deininger Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis Blood, October 15, 2009; 114(16): 3459 - 3463. [Abstract] [Full Text] [PDF] D. H. Kim, L. Sriharsha, W. Xu, S. Kamel-Reid, X. Liu, K. Siminovitch, H. A. Messner, and J. H. Lipton Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia Clin. Cancer Res., July 15, 2009; 15(14): 4750 - 4758. [Abstract] [Full Text] [PDF] G. D. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova, C. D. Blanke, H. Joensuu, and M. von Mehren Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors J. Clin. Oncol., July 1, 2009; 27(19): 3141 - 3147. [Abstract] [Full Text] [PDF] L. Noens, M.-A. van Lierde, R. De Bock, G. Verhoef, P. Zachee, Z. Berneman, P. Martiat, P. Mineur, K. Van Eygen, K. MacDonald, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Blood, May 28, 2009; 113(22): 5401 - 5411. [Abstract] [Full Text] [PDF] M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood, May 7, 2009; 113(19): 4497 - 4504. [Abstract] [Full Text] [PDF] T. W. Kim, M.-H. Ryu, H. Lee, S. J. Sym, J.-L. Lee, H. M. Chang, Y. S. Park, K. H. Lee, W. K. Kang, D. B. Shin, et al. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Oncologist, May 1, 2009; 14(5): 540 - 547. [Abstract] [Full Text] [PDF] F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party Blood, April 9, 2009; 113(15): 3428 - 3434. [Abstract] [Full Text] [PDF] E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF] D. Bixby and M. Talpaz Imatinib As Frontline Therapy for Patients with Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2009; 2009(1): 395 - 401. [Abstract] [Full Text] [PDF] M. C. Heinrich, S. George, S. Bauer, and J. A. Fletcher Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies ASCO Educational Book, January 1, 2009; 2009(1): 694 - 699. [Abstract] [Full Text] [PDF] D. L White, V. A Saunders, P. Dang, A. Frede, L. Eadie, S. Soverini, F. Quarantelli, P. Lin, M. Thornquist, D.-W. Kim, et al. CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 3187 - 3187. [Abstract] T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy Blood, November 15, 2008; 112(10): 3965 - 3973. [Abstract] [Full Text] [PDF] A. Petain, D. Kattygnarath, J. Azard, E. Chatelut, C. Delbaldo, B. Geoerger, M. Barrois, S. Seronie-Vivien, A. LeCesne, G. Vassal, et al. Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults Clin. Cancer Res., November 1, 2008; 14(21): 7102 - 7109. [Abstract] [Full Text] [PDF] S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, M. Krajinovic, and F.-X. Mahon Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood, September 1, 2008; 112(5): 2024 - 2027. [Abstract] [Full Text] [PDF] R. A. Larson, B. J. Druker, F. Guilhot, S. G. O'Brien, G. J. Riviere, T. Krahnke, I. Gathmann, Y. Wang, and for the IRIS (International Randomized Interferon Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood, April 15, 2008; 111(8): 4022 - 4028. [Abstract] [Full Text] [PDF] S. D Baker Pharmacokinetic Considerations for Molecularly Targeted Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 705 - 709. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] M. W. Deininger Milestones and Monitoring in Patients with CML Treated with Imatinib Hematology, January 1, 2008; 2008(1): 419 - 426. [Abstract] [Full Text] [PDF] J. E. Cortes Imatinib and Beyond--Therapy of CML in 2008 ASCO Educational Book, January 1, 2008; 2008(1): 307 - 312. [Abstract] [Full Text] [PDF] G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF] C. Blasdel, M. J. Egorin, T. F. Lagattuta, B. J. Druker, and M. W. Deininger Therapeutic drug monitoring in CML patients on imatinib Blood, September 1, 2007; 110(5): 1699 - 1701. [Full Text] [PDF] F.-X. Mahon, S. Picard, G. Marit, P. Robinson, and M. Molimard Use of therapeutic drug monitoring in CML patients on imatinib Blood, September 1, 2007; 110(5): 1701 - 1701. [Full Text] [PDF] A. Sparreboom Unexplored Pharmacokinetic Opportunities with Microdosing in Oncology Clin. Cancer Res., July 15, 2007; 13(14): 4033 - 4034. [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2006-07-036012v1 109/8/3496    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Picard, S. Articles by Mahon, F.-X. Search for Related Content PubMed PubMed Citation Articles by Picard, S. Articles by Mahon, F.-X. Related Collections Oncogenes and Tumor Suppressors Brief Reports Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020